BI Asset Management Fondsmaeglerselskab A S Decreases Stake in Humana Inc. $HUM

BI Asset Management Fondsmaeglerselskab A S cut its stake in shares of Humana Inc. (NYSE:HUM) by 63.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,251 shares of the insurance provider’s stock after selling 10,808 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Humana were worth $1,601,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HUM. Capital International Investors purchased a new stake in Humana during the third quarter valued at approximately $707,670,000. Norges Bank purchased a new stake in shares of Humana in the fourth quarter worth approximately $456,632,000. Massachusetts Financial Services Co. MA raised its holdings in shares of Humana by 28.9% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock worth $1,151,759,000 after buying an additional 1,008,514 shares during the period. Neuberger Berman Group LLC raised its holdings in shares of Humana by 2,855.5% in the third quarter. Neuberger Berman Group LLC now owns 530,775 shares of the insurance provider’s stock worth $138,092,000 after buying an additional 512,816 shares during the period. Finally, 8 Knots Management LLC raised its holdings in shares of Humana by 671.0% in the second quarter. 8 Knots Management LLC now owns 441,623 shares of the insurance provider’s stock worth $107,968,000 after buying an additional 384,345 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Up 2.3%

Shares of NYSE:HUM opened at $364.11 on Wednesday. Humana Inc. has a 52-week low of $163.11 and a 52-week high of $365.22. The stock has a market cap of $43.72 billion, a P/E ratio of 38.94, a price-to-earnings-growth ratio of 2.04 and a beta of 0.76. The business’s 50 day moving average is $255.95 and its 200 day moving average is $234.19. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.66.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The company had revenue of $39.65 billion for the quarter, compared to analysts’ expectations of $39.37 billion. During the same quarter in the prior year, the firm earned $11.58 earnings per share. Humana’s revenue was up 23.5% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000- EPS. Sell-side analysts predict that Humana Inc. will post 9 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Friday, June 26th. Humana’s dividend payout ratio (DPR) is 37.86%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald assumed coverage on Humana in a report on Wednesday, May 20th. They issued an “overweight” rating on the stock. Oppenheimer upgraded Humana from an “outperform” rating to an “outperform” rating in a report on Wednesday, May 20th. Evercore increased their price target on Humana from $195.00 to $250.00 in a report on Thursday, April 30th. Piper Sandler reiterated a “neutral” rating and issued a $254.00 price target (up from $182.00) on shares of Humana in a report on Wednesday, May 13th. Finally, Morgan Stanley increased their price target on Humana from $217.00 to $249.00 and gave the stock an “underweight” rating in a report on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, fourteen have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, Humana presently has a consensus rating of “Hold” and an average price target of $286.13.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.